Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of teriflunomide on T-cell subpopulations in relapsing-remitting multiple sclerosis
2016-001515-20Phase 4Terminated
- Sponsor
- Policlinico Gemelli
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of teriflunomide in relapsing-remitting multiple sclerosis (RRMS), sponsored by Policlinico Gemelli. Primary endpoint: Correlation of T-cell subpopulation change with clinical and radiological response. Started Feb 2018; status: terminated.
02
Drugs
teriflunomide
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2016-001515-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001515-20.